During 2023 SciBase SciBase has continued to take important steps forward with continued strong sales growth in Germany, important reimbursement progress in the U.S. and continued to establish the Company within the skin barrier application area. In the fourth quarter of 2022 the Company signed a strategic collaboration agreement with Kenvue (formerly Johnson & Johnson Consumer Health) to develop a screening product to identify infants that are at increased risk for developing atopic dermatitis in the first year of life. Sales growth is the key for SciBase and the Company has, as per the third quarter 2023, had 13 consecutive quarters of sales growth (compared to the same periods in previous years). To continue the accelerated growth, SciBase prioritizes three key areas in line with the Company’s strategy: continued expansion in the U.S. through broader reimbursement, continued profitable sales growth in Germany, and the development of applications based on the evaluation of the skin barrier.

Unlocking US market reimbursement for continued growth

  • SciBase's Nevisense is the sole FDA approved point-of-care device available for melanoma detection in the US.
  • Our success is validated by the enthusiastic adoption of our technology at the first 60 US sites.
  • Collaborations with large dermatology practice groups, such as ADCS, are driving cost-effective market penetration.
  • Substantial progress has been made in securing Medicare reimbursement, with the first two regions covering our method through a fee schedule.
  • We are actively engaged with private payers and additional Medicare regions to expand accessibility.
  • Our presence in the US market holds immense growth potential.